04482nam 2200565 450 991013652930332120170920010705.00-323-46278-2(CKB)3710000000840762(EBL)4658778(MiAaPQ)EBC4658778(EXLCZ)99371000000084076220160908h20162016 uy 0engur|n|---|||||rdacontentrdamediardacarrierGastrointestinal neoplasia /editors, Paul J. Limburg, Dan A. Dixon ; consulting editor, Gary W. FalkPhiladelphia, Pennsylvania :Elsevier,2016.©20161 online resource (228 p.)Gastroenterology Clinics of North America,0889-8553 ;Volume 45, Number 3Includes index."Clinics Review Articles"--Cover.0-323-46257-X Title page; Table of Contents; Copyright; Contributors; Forthcoming Issues; Preface; Esophageal Cancer; Key points; Introduction; Squamous cell carcinoma of the esophagus; Adenocarcinoma of the esophagus; Barrett's esophagus; Diagnosis; Staging; Treatment; The future of diagnosis and management; Other esophageal malignancies; Summary; Supplementary data; Current Perspectives on Gastric Cancer; Key points; Global impact of gastric cancer; Gastric cancer causes and risk factors; Gastric cancer classification; Gastric cancer prevention; Screening and surveillance; Diagnostic evaluationClinical managementPrognosis and survivorship; Pancreatic Cancer: A Review; Key points; Introduction and public health concerns; Molecular pathways/genetics; Risk factors; Early detection; Diagnostic evaluation; Clinical management; Surgery; Chemotherapy; Survivorship; Future directions; Summary; Small Bowel Adenocarcinoma; Key points; Introduction; Epidemiology; Tumor phenotyping; Risk factors for small bowel adenocarcinoma; Diagnosis of small bowel adenocarcinoma; Prognosis; Treatment; Summary; Colorectal Cancer: Genetics is Changing Everything; Key points; Introduction; Molecular pathwaysPublic health burdenRisk and protective factors; Screening and early detection; Diagnostic evaluation; Prognosis; Clinical management; Survivorship; Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy; Key points; Introduction; Case series from the era before imatinib therapy; Selected trials of adjuvant imatinib; Z9000 (1-year imatinib); Z9001 (0 vs 1-year adjuvant imatinib); European Organisation for Research and Treatment of Cancer intergroup trial (0 vs 2-year adjuvant imatinib)Scandinavian Sarcoma Group XVIII/Arbeitsgemeinschaft Internistische Onkologie (1- vs 3-year adjuvant imatinib)Ongoing adjuvant trials; Neoadjuvant therapy; Reimaging; Sensitivity of gastrointestinal stromal tumor-specific KIT and PDGFRA mutations to imatinib; National and international guidelines; Commentary; Neuroendocrine Tumors; Key points; Introduction; Clinical presentations of gastroenteropancreatic neuroendocrine tumors; Diagnostic modalities; Markers of neuroendocrine tumors disease; Management; Summary; Heritable Gastrointestinal Cancer Syndromes; Key points; Genes and cancerColorectal cancerColonic polyposis syndromes; Gastric cancer; Pancreatic adenocarcinoma; Clinical approach to genetic risk assessment for gastrointestinal cancer risk; Molecular Detection of Gastrointestinal Neoplasia: Innovations in Early Detection and Screening; Key points; Introduction; Mechanisms, media, and markers; A glimpse at emergent and experimental new molecular tools for gastrointestinal cancer screening; Summary; The Role of the Microbiome in Gastrointestinal Cancer; Key points; Introduction; Gastric cancer; Helicobacter pyloriBacterial and host factors affecting the propensity toward gastric cancerGastroenterology clinics of North America ;Volume 45, Number 3.EndoscopyEndoscopesGastroenterologyEndoscopy.Endoscopes.Gastroenterology.616.3307545Limburg Paul J.Dixon Dan A.Falk Gary W.MiAaPQMiAaPQMiAaPQBOOK9910136529303321Gastrointestinal neoplasia3404638UNINA